TL;DR
For the first time in the US, an AI system is autonomously prescribing medication to patients in Utah, triggering a regulatory standoff that could define the legal limits of autonomous AI in healthcare.
What happened
- Doctronic launched an autonomous AI prescription renewal pilot on January 6, 2026, under Utah's AI Learning Laboratory (regulatory sandbox) program.
- The pilot covers 191 medications for chronic conditions including hypertension, diabetes, and depression, allowing 30-, 60-, or 90-day renewals of existing prescriptions.
- In Phase One (current), a licensed physician reviews every AI recommendation before it reaches a pharmacy. Phase Two, where AI submits directly to pharmacies, has not yet begun for any medication group.
- Early data (January through April 2026): the AI recommended renewal in 72% of cases, escalated 28% to physicians, and reviewing physicians agreed with 91% of AI recommendations.
- Utah's Medical Licensing Board has demanded immediate suspension of the pilot. The program continues regardless, and Doctronic is in active talks with Arizona, Texas, and Wyoming about expansion.
Why it matters
- The sandbox agreement does not resolve whether AI performing clinical judgment constitutes unlicensed practice of medicine under Utah Code 58-67-301, a question with national implications.
- Utah's corporate practice of medicine statute (58-67-802) requires a licensed individual to conduct medical practice. An AI cannot hold a medical license, creating direct legal exposure.
- A second company, Legion Health, has already signed a similar agreement for non-controlled psychiatric medication renewals, signaling this is not a one-off experiment.
- The 12-month regulatory mitigation agreement runs October 2025 through October 2026. Doctronic must request an extension within 30 days of expiration or the program lapses legally.
- If Phase Two activates, AI prescribes with no physician in the loop at point of dispensing, a threshold no US jurisdiction has formally crossed, raising FDA device classification and liability questions that the sandbox cannot waive.
What to watch next
- Whether OAIP approves a 12-month extension before the October 2026 deadline, and whether the independent review of Doctronic's self-reported outcome data surfaces discrepancies.
- Whether any medication group reaches the revised 250-filled-prescription threshold per category, triggering a Phase Two decision and the first fully autonomous AI prescribing in US history.
- Regulatory responses in Arizona, Texas, and Wyoming, where Doctronic is actively negotiating, which would signal whether this model scales nationally or stalls at Utah's borders.
Originally published on Present of AI, a daily source-linked AI news timeline. Read the full timeline or browse the open dataset.